JP2023529371A5 - - Google Patents

Info

Publication number
JP2023529371A5
JP2023529371A5 JP2022574541A JP2022574541A JP2023529371A5 JP 2023529371 A5 JP2023529371 A5 JP 2023529371A5 JP 2022574541 A JP2022574541 A JP 2022574541A JP 2022574541 A JP2022574541 A JP 2022574541A JP 2023529371 A5 JP2023529371 A5 JP 2023529371A5
Authority
JP
Japan
Prior art keywords
dnaj
fusion protein
synuclein
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035958 external-priority patent/WO2021248038A1/en
Publication of JP2023529371A publication Critical patent/JP2023529371A/ja
Publication of JP2023529371A5 publication Critical patent/JP2023529371A5/ja
Pending legal-status Critical Current

Links

JP2022574541A 2020-06-05 2021-06-04 シヌクレイノパチーの処置のための組成物および方法 Pending JP2023529371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035297P 2020-06-05 2020-06-05
US63/035,297 2020-06-05
PCT/US2021/035958 WO2021248038A1 (en) 2020-06-05 2021-06-04 Compositions and methods for the treatment of synucleinopathies

Publications (2)

Publication Number Publication Date
JP2023529371A JP2023529371A (ja) 2023-07-10
JP2023529371A5 true JP2023529371A5 (https=) 2024-06-10

Family

ID=76708439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574541A Pending JP2023529371A (ja) 2020-06-05 2021-06-04 シヌクレイノパチーの処置のための組成物および方法

Country Status (6)

Country Link
US (1) US20230234997A1 (https=)
EP (1) EP4161953A1 (https=)
JP (1) JP2023529371A (https=)
CN (1) CN116096737A (https=)
CA (1) CA3183251A1 (https=)
WO (1) WO2021248038A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024229777A1 (zh) * 2023-05-11 2024-11-14 深圳先进技术研究院 一种aav载体及其应用
CN116590342B (zh) * 2023-05-11 2026-04-03 普递瑞(上海)医药有限公司 一种aav载体及其应用
CN117402251B (zh) * 2023-12-15 2024-02-23 中国医学科学院基础医学研究所 一种抗小g蛋白rbj的抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999061601A2 (en) 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
CN1246532A (zh) * 1998-08-31 2000-03-08 复旦大学 人热休克关联蛋白编码序列、其编码的多肽及制备方法
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
JP5136766B2 (ja) 2004-12-15 2013-02-06 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラベクター
US20110201686A1 (en) * 2006-06-23 2011-08-18 Yousef Al-Abed Inhibitors of ASS and Synuclein Aggregation
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US9169492B2 (en) 2010-02-05 2015-10-27 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US9758807B2 (en) * 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
US11390899B2 (en) * 2016-09-26 2022-07-19 SOLA Biosciences, LLC Cell-associated secretion-enhancing fusion proteins
US12162929B2 (en) * 2018-02-19 2024-12-10 New York University Alpha-synuclein single domain antibodies
US20230173049A1 (en) * 2019-12-31 2023-06-08 The Johns Hopkins University Fusion proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
ES2230569T3 (es) Funciones accesorias para uso en la produccion de viriones aav recombinantes.
JP2020522269A5 (https=)
AU2018303230B2 (en) Improved AAV capsid production in insect cells
CA2985945C (en) Capsid
ES2703814T3 (es) Terapia génica para la enfermedad de Fabry
Lu Recombinant adeno-associated virus as delivery vector for gene therapy—a review
ES2302331T3 (es) Vectores que codifican genomas de aav recombinantes.
US10413598B2 (en) Factor IX gene therapy
JP2023524414A5 (https=)
US20170067028A1 (en) Radiolabeling of adeno associated virus
US20110171262A1 (en) Parvoviral capsid with incorporated gly-ala repeat region
JP2022508182A5 (https=)
JP2021512649A5 (https=)
JP2023529371A5 (https=)
KR20160131032A (ko) 곤충 세포에서 생산된 더욱 향상된 aav 벡터
TW201546285A (zh) 腺相關病毒因子viii載體
JP2025069281A (ja) 調節可能な発現系
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
JP2017529395A5 (https=)
JP2023524024A5 (https=)
JP2023520927A5 (https=)
JP2023537358A5 (https=)
JP2022542829A5 (https=)
JP2025513887A (ja) 肝臓における遺伝子発現を脱標的化するための要素
US10105450B2 (en) Promoter compositions